Question

A client who has developed renal failure with associated high serum phosphate levels. To avoid the development of osteodystrophy, the healthcare provider will try to avoid phosphate-binding agents that contain which compound?

a. Calcium acetate
b. Aluminum salts
c. Sevelamer hydrochloride
d.Calcium carbonate

Answer 1

Healthcare providers avoid aluminum salts in phosphate-binding agents for patients with renal failure and high serum phosphate to prevent osteodystrophy and potential aluminum toxicity.

Step-by-step explanation:

To avoid the development of osteodystrophy in a client with renal failure and associated high serum phosphate levels, healthcare providers generally try to avoid phosphate-binding agents that contain aluminum salts.

Aluminum-containing binders can lead to toxicity, particularly in patients with impaired renal function, and should be avoided if possible. Instead, other phosphate-binding agents such as calcium acetate, calcium carbonate, or sevelamer hydrochloride, which do not contain aluminum, are often used to control hyperphosphatemia.